Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Pediatric clinical pharmacology: an introduction to a series of educational papers


Drug therapy is a very powerful tool to improve the medical outcome of children. Despite this fact, pediatricians still commonly prescribe drug formulations that were developed for adults. In this series of educational papers related to pediatric clinical pharmacology, we aim to raise awareness on different aspects of clinical pharmacology in children, covering neonatal clinical pharmacology, formulation-related issues, ethical aspects of clinical research, pharmacovigilance, and training in pediatric clinical pharmacology. We want to illustrate the relevance of this re-emerging research field for the practicing clinician, although we are very much aware that these topics do not fully cover the multifaceted landscape of pediatric clinical pharmacology. We hope that many readers will reconsider their daily clinical practices and will be stimulated to collaborate to further improve pediatric drug therapy throughout Europe and beyond.

This is a preview of subscription content, log in to check access.


  1. 1.

    Allegaert K, Langhendries JP, van den Anker JN (2012) Educational paper: do we need neonatal clinical pharmacologists? Eur J Pediatr. doi:10.1007/s00431-012-1734-4

  2. 2.

    Anderson BJ, Allegaert K, Holford NH (2006) Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 165:819–829

  3. 3.

    Arnott J, Hesselgreaves H, Nunn AJ, Peak M, Pirmohamed M, Smyth RL, Turner MA, Young B (2012) What can we learn from parents about enhancing participation in pharmacovigilance? Br J Clin Pharmacol. doi:10.1111/j.1365-2125.2012.04441.x

  4. 4.

    Bos W, Tromp K, Tibboel D, Pinxten W (2012) Ethical aspects of clinical research with minors. Eur J Pediatr. doi:10.1007/s00431-012-1856-8

  5. 5.

    Choonara I (2012) Educational paper: aspects of clinical pharmacology in children-pharmacovigilance and safety. Eur J Pediatr. doi:10.1007/s00431-012-1871-9

  6. 6.

    De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA (2011) The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 67(Suppl 1):5–16

  7. 7.

    Ernest TB, Craig J, Nunn A, Salunke S, Tuleu C, Breitkreutz J, Alex R, Hempenstall J (2012) Preparation of medicines for children—a hierarchy of classification. Int J Pharm 435:124–130

  8. 8.

    Hurwitz R, Blackmore R, Hazell P, Williams K, Woolfenden S. Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents. (2012) Cochrane Database Syst Rev 3:CD008372

  9. 9.

    Knibbe CA, Danhof M (2011) Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? Int J Pharm 415:9–14

  10. 10.

    Kulo A, de Hoon JN, Allegaert K (2012) The propylene glycol research project to illustrate the feasibility and difficulties to study toxicokinetics in neonates. Int J Pharm 435:112–114

  11. 11.

    Ramet J (2005) What the paediatricians need—the launch of paediatric research in Europe. Eur J Pediatr 164:263–265

  12. 12.

    Rich W, Finer NN, Gantz MG, Newman NS, Hensman AM, Hale EC, Auten KJ, Schibler K, Faix RG, Laptook AR, Yoder BA, Das A, Shankaran S, SUPPORT and Generic Database Subcommittees of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (2012) Enrollment of extremely low birth weight infants in a clinical research study may not be representative. Pediatrics 129:480–484

  13. 13.

    Sakolsky D, Birmaher B (2012) Developmentally informed pharmacotherapy for child and adolescent depressive disorders. Child Adolesc Psychiatr Clin N Am 21:313–325

  14. 14.

    Salunke S, Giacoia G, Tuleu C (2012) The STEP (safety and toxicity of excipients for paediatrics) database. Part 1—a need assessment study. Int J Pharm 435:101–111

  15. 15.

    Santovena A, Hernandez-Paiz Z, Farina JB (2012) Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide. Int J Pharm 423:360–364

  16. 16.

    Smits A, Kulo A, de Hoon JN, Allegaert K (2012) Pharmacokinetics of drugs in neonates: pattern recognition beyond compound specific observations. Curr Pharm Des 18:3119–3146

  17. 17.

    Tuleu C (2012) ‘Formulating better medicines for children’—still paving the road. Int J Pharm 435:99–100

  18. 18.

    Tuleu C, Breitkreutz J (2012) Educational paper: formulation-related issues in pediatric clinical pharmacology. Eur J Pediatr. doi:10.1007/s00431-012-1872-8

  19. 19.

    Turner MA, Storme T (2012) European study of neonatal excipient exposure (ESNEE). Eur J Hosp Pharm 19:67

  20. 20.

    Van den Anker J, et al. (2012) Educational paper. Training in paediatric clinical pharmacology: the GRIP initiative. Eur J Pediatr (in press)

  21. 21.

    Veal GJ, Hartford CM, Stewart CF (2010) Clinical pharmacology in the adolescent oncology patient. J Clin Oncol 28:4790–4799

  22. 22.

    Whitney SN (2012) The python’s embrace: clinical research regulation by institutional review boards. Pediatrics 129:576–578

Download references


Karel Allegaert is supported by the Fund for Scientific Research, Flanders (Fundamental Clinical Investigatorship 1800209N).

Author information

Correspondence to Karel Allegaert.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Allegaert, K. Pediatric clinical pharmacology: an introduction to a series of educational papers. Eur J Pediatr 172, 289–292 (2013).

Download citation


  • Developmental pharmacology
  • Newborn
  • Pharmacovigilance
  • Ethics
  • Formulation
  • Training